Thu, Sep 18, 2014, 4:20 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Thoratec Corp. Message Board

  • bigsmartsta bigsmartsta Oct 4, 2013 8:03 PM Flag

    Last Time An Insider Sold Was June 17 And Was 653 Shares

    Looks like GREAT NEWS is coming.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Lot's of selling this month as we approach 52 week high. What do you make of that p4a? I've been buying some SSH as a class 3 play and still holding on to my THOR for many good reasons.

      Sentiment: Hold

      • 1 Reply to drdewpepper
      • Doc

        1- I view the current trading pattern as accumulation by those not yet having a core position.

        2- The coming earning cc on Oct 30 will be the key driver.

        3- THOR, with the HM3, PHP, improved Centimag, FILVAS, DuraHeart II, now has the means to get to the next level within the HUGE global arena of MCSD.

        4- Furthermore, the FDA provides a pseudo monopoly. Samsung can't design a copy here as it did to AAPL. That's a HUGE advantage no other industry has.

        5- THOR has recently over-burdened itself with the HUGE pipeline. For example, taking on the DuraHeart has resulted in an additional $7 million expense. If THOR can still show accelerated earnings despite the cost of the pipeline, I can see triple digits.

        6- I am not adding to my position until Oct 30. I assume those that have more insight, such as Analysts directly talking to MDs, are willing to add stock in the $38 region but will not aggressively purchase shares at the $40 handle UNLESS it's an initial core holding, i.e., those not having a position.

        7- I see the Aspirin requirement of 161 mg to 325 mg DAILY of the HVAD and probably the MVAD as a HUGE disadvantage for HTWR. As you know in Europe clinical prospective and retrospective studies, a daily aspirin of the above magnitude can produce a myriad of problems including accelerated macular degeneration, asymptomatic micro-brain-bleeding, gastrointestinal bleeding, etc., etc. Simply put, HTWR will become an also ran when the HM3 emerges in Q1 2014 in clinical trials.

26.40+0.25(+0.96%)4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.